

HANDBOOK OF

**Pharmacokinetic/  
Pharmacodynamic  
Correlation**

EDITED BY

**Hartmut Derendorf  
Günther Hochhaus**



CRC PRESS

### Library of Congress Cataloging-in-Publication Data

Handbook of pharmacokinetic/pharmacodynamic correlation / edited by Hartmut Derendorf, Gunther Hochhaus.  
p. cm.

Includes bibliographical references and index.

ISBN 0-8493-8303-X

1. Pharmacokinetics. 2. Drugs—Physiological effect.

I. Derendorf, Hartmut. II. Hochhaus, Günther.

[DNLM: 1. Pharmacokinetics. 2. Pharmacology. 3. Dose-Response Relationship, Drug. 4. Models, Theoretical; QV 38 H2365 1995]

RM301.5H36 1995

615'.7—dc20

DNLM/DLC

94-22365

CIP

This book contains information obtained from authentic and highly regarded sources. Reprinted material is quoted with permission, and sources are indicated. A wide variety of references are listed. Reasonable efforts have been made to publish reliable data and information, but the author and the publisher cannot assume responsibility for the validity of all materials or for the consequences of their use.

Neither this book nor any part may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, microfilming, and recording, or by any information storage or retrieval system, without prior permission in writing from the publisher.

All rights reserved. Authorization to photocopy items for internal or personal use, or the personal or internal use of specific clients, may be granted by CRC Press LLC, provided that \$.50 per page photocopied is paid directly to Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923 USA. The fee code for users of the Transactional Reporting Service is ISBN 0-8493-8303-X/95/\$0.00+\$.50. The fee is subject to change without notice. For organizations that have been granted a photocopy license by the CCC, a separate system of payment has been arranged.

The consent of CRC Press LLC does not extend to copying for general distribution, for promotion, for creating new works, or for resale. Specific permission must be obtained in writing from CRC Press LLC for such copying.

Direct all inquiries to CRC Press LLC, 2000 N.W. Corporate Blvd., Boca Raton, Florida 33431.

**Trademark Notice:** Product or corporate names may be trademarks or registered trademarks, and are used only for identification and explanation, without intent to infringe.

Visit the CRC Press Web site at [www.crcpress.com](http://www.crcpress.com)

© 1995 by CRC Press LLC

No claim to original U.S. Government works  
International Standard Book Number 0-8493-8303-X  
Library of Congress Card Number 94-22365

Printed in the United States of America

8 9 0

Printed on acid-free paper

Copyrighted material

Handbook of

---

**Pharmacokinetic/  
Pharmacodynamic  
Correlation**

*Edited by*

**Hartmut Derendorf, Ph. D.  
Günther Hochhaus, Ph.D.**

*University of Florida  
Gainesville, Florida*



**CRC Press**

**Boca Raton London New York Washington, D.C.**

## DOSE OPTIMIZATION BASED ON PHARMACOKINETIC- PHARMACODYNAMIC MODELING

Günther Hochhaus and Hartmut Derendorf

### INTRODUCTION

In recent years, pharmacokinetic-pharmacodynamic relationships have received considerable attention since it was realized that they provide a causative link between drug delivery and/or drug dosing and therapeutic outcome. A drug in a certain dosage form is administered to a patient with a certain dosing schedule. This results in a certain concentration profile at the sites of effect and side effect which is the reason for the observed drug-induced changes in the patient. Pharmacokinetic-pharmacodynamic modeling (PK-PD modeling) is an attempt to quantify these relationships with the goal to explain observed phenomena and derive an optimum dosing recommendation. The questions that are to be answered are

- What is the best dose?
- What is the best dosing regimen?
- What is the best route of administration?
- What is the best dosage form?

*Pharmacokinetics* can be looked at as “what the body does to the drug”, whereas *pharmacodynamics* is “what the drug does to the body”. Pharmacokinetics describes the relationship between drug and metabolite concentrations and time. Pharmacodynamics describes the relationships between pharmacological effects and drug and/or metabolite concentrations. Combination of these two areas, PK-PD modeling, leads to the therapeutically most relevant relationship between pharmacological effects and time (Figure 1).

Whereas pharmacokinetics is an established routine discipline with widely accepted principles, pharmacodynamics is still an emerging field with many open questions. One reason for the delay in this development was the lack of techniques that allowed reproducible measurement of drug effects over time. A drug effect can be defined as any drug-induced change in a physiological parameter when compared to the respective predose or baseline value. The baseline value is the value of the same physiological parameter in the absence of drug dosing. Baseline values do not necessarily have to be constant but can change, e.g., as a function of time of day or food intake. Furthermore, the term *effect* has to be clearly separated from the term *efficacy*. Efficacy is the sum of all therapeutically beneficial drug effects and is the most relevant target parameter in PK-PD modeling. However, in many PK-PD studies there is little evidence if the pharmacodynamic effect parameter used has any correlation to the desired efficacy and is a validated surrogate marker.

### PHARMACODYNAMIC MODELS

At present, the most commonly used pharmacodynamic models are the

- Fixed effect model
- Linear model
- Log-linear model
- $E_{\max}$  model
- Sigmoid  $E_{\max}$  model




FIGURE 1. Schematic relationship between pharmacokinetics, pharmacodynamics, and PK-PD modeling.

### FIXED EFFECT MODEL

A fixed effect model is a statistical approach that, for a certain drug concentration, quantifies the likelihood of a defined effect to be present or not. For example, at a digoxin plasma concentration of 2.0 ng/ml there is a 50% probability to observe digoxin toxicity, whereas at a concentration of 4.1 ng/ml the probability is 90%.<sup>1</sup> This approach may be useful in the clinical setting but has major limitations for the prediction of complete effect-time profiles.

### LINEAR MODEL

The linear model assumes a direct proportionality between drug concentration and drug effect:

$$E = E_0 + m \cdot C \quad (1)$$

where  $E$  is the effect measured,  $C$  the drug concentration,  $E_0$  the baseline effect, and  $m$  a proportionality factor. The linear model is the one that intuitively is the most popular, although it rarely applies. One problem is that in today's educational system much emphasis is given to pharmacokinetic principles where dose-proportional changes in drug concentrations are very common. This concept is sometimes inappropriately applied to pharmacodynamic predictions expecting dose-proportional changes in drug effects.

### LOG-LINEAR MODEL

A much more common situation than the linear model is the log-linear model, with

$$E = m \cdot \log C + b \quad (2)$$

where  $m$  and  $b$  are the slope and intercept of a plot of effect  $E$  vs. the logarithm of the concentration  $C$ . This model is applicable in many situations and can be considered a special case of the  $E_{\max}$  model.

### $E_{\max}$ MODEL

In the  $E_{\max}$  model, concentration and effect are related as:

$$E = \frac{E_{\max} \cdot C}{E_{50} + C} \quad (3)$$

where  $E_{\max}$  is the maximum effect possible and  $E_{50}$  is the concentration where 50% of the maximum effect is observed. This equation is equivalent to the relationship that can be derived for the equilibrium interaction of a drug ( $D$ ) with a site of action ( $R$ ), e.g., a receptor, enzyme, or ion channel.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.